128.61 0.00 (0.00%)
After hours: 4:28PM EST
|Bid||128.00 x 1100|
|Ask||133.00 x 1000|
|Day's Range||127.30 - 132.97|
|52 Week Range||90.14 - 179.65|
|Beta (3Y Monthly)||3.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||173.17|
These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January
CORAL GABLES, FL / ACCESSWIRE / January 15,2019 / Marijuana stocks have had quite a solid week during the beginning of January. American Premium Water Corporation (HIPH), GW Pharmaceuticals plc (GWPH), Cronos Group Inc (CRON) (CRON), and Charlotte's Web Holdings Inc (CWBHF) are 4 pot stocks that are bringing the heat. American Premium Water Corporation (HIPH) is a company you may not have heardof, but could benefit from taking a look at.
Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million. In the third quarter, the company’s revenues declined ~40% YoY to reach $18.3 million from $30.7 million. Wall Street analysts estimate that INSYS Therapeutics is expected to generate revenues of $17.95 million in the fourth quarter of fiscal 2018, which represents a ~42.99% YoY decline. Analysts also estimate that INSYS Therapeutics will report net revenues of $83.74 million for fiscal 2018, which represents a ~40.48% YoY decline. Analysts estimate that GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA), INSYS Therapeutics’ peers in the cannabinoid drugs market, will report net revenues of $8.7 million and $10.9 million, respectively. GW Pharmaceuticals is expected to deliver ~13.52% YoY revenue growth in fiscal 2018. INSYS Therapeutics and Lunatus signed a licensing agreement for the commercialization of Subsys in the Middle East market. The agreement could boost INSYS Therapeutics’ global footprint and business growth. ## Expenditure trends In the first nine months of 2018, INSYS Therapeutics’ cost of revenue amounted to $8.2 million compared to $16.0 million in the same period the prior year. Wall Street analysts anticipate INSYS Therapeutics’ cost of revenue to be around $9.7 million in fiscal 2018. In the first nine months of 2018, INSYS Therapeutics’ net expenses in sales and marketing (or S&M) amounted to $25.5 million compared to $41.7 million in the same period the prior year. INSYS Therapeutics reported R&D (research & development) and G&A (general & administrative) expenses of $43.2 million and $29.3 million, respectively, compared to $46.6 million and $31.8 million in the same period the prior year. Wall Street analysts estimate that the company’s S&M, G&A, and R&D expenditure will be around $32.49 million, $89.50 million, and $58.78 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 3 - How INSYS Therapeutics’ Earnings Were Trending
On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of market on December 31. On January 2, 2019, INSYS Therapeutics stock price grew ~24.29% to reach $4.35 from its prior day close of $3.50 on December 31, 2018.
CORAL GABLES, FL / ACCESSWIRE / January 11,2019 / The marijuana industry has been anything but safe over the course of the past year to two years, during the course of which top players in the industry saw huge boosts in investor interest. ), OrganiGram Holdings Inc (OGRMF) (OGI.V), Namaste Technologies Inc (NXTTF), and GW Pharmaceuticals Plc (GWPH) are 4 pot stocks that could make moves on Friday. The Company has been referred to as the "Priceline of Pot" by several sources, and similarly to the site which provides travel deals, Leafbuyer is the most comprehensive online source for cannabis deals and specials.
Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Growth drivers The US FDA (Food and Drug Administration) confirmed GW Pharmaceuticals’ (GWPH) Epidiolex seven-year orphan drug exclusivity. The company anticipates a six-month extension for orphan drug exclusivity for pediatric patients. The USPTO granted major favorable patents associated with the use of CBD in epilepsy. The patents include claims for certain seizure types related to Dravet syndrome and LGS. The patents of GW Pharmaceuticals’ Cannabinoids will expire only after 2035. The market exclusivity, orphan drug exclusivity, and patents are expected to boost Epidiolex’s growth in 2019 and beyond. ## Growth opportunities GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results. GW Pharmaceuticals targets Sativex approval for the treatment of multiple sclerosis spasticity. The company received regulatory approval in 25 countries outside the US for the treatment of individuals with spasticity associated with multiple sclerosis. GW Pharmaceuticals is conducting research for evaluating the potential of Sativex for the treatment of schizophrenia and other neurological disorders. GW Pharmaceuticals conducted phase 2 trials of CBD:THC for the evaluation of its efficacy in the treatment of Glioblastoma. GW Pharmaceuticals received an orphan drug designation from the US FDA and EMA (European Medicines Agency) for CBD:THC for the treatment of Glioblastoma. GW Pharmaceuticals has also completed a phase 1 trial of its Neonatal Hypoxic-Ischemic Encephalopathy intravenous CBD program. The company anticipates initiating a phase 2 trial during the first half of 2019. THC could boost the company’s growth in the long term. The growth of GW Pharmaceuticals could boost the share prices of the Horizons Marijuana Life Sciences Index ETF (HMLSF). GW Pharmaceuticals makes up ~9.27% of HMLSF’s total portfolio holding. Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending
Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Earnings trends In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively, compared to -$170.5 million and -$0.56 in the prior year. In the fourth quarter of 2018, GW Pharmaceuticals reported net income and EPS of -$79.9 million and -$0.23, respectively, compared to -$53.9 million and -$0.18 in the same period the prior year. ## Expenditure trends In fiscal 2018, GW Pharmaceuticals (GWPH) reported cost of product sales of $6.0 million compared to $4.5 million in fiscal 2017. In fiscal 2018, the company’s R&D (research and development) and SG&A (selling, general, and administrative) expenses amounted to $153.7 million and $141.8 million, respectively, compared to $112.2 million and $58.0 million in fiscal 2017. ## Growth drivers GW Pharmaceuticals’ Epidiolex demonstrated a positive result and achieved the primary endpoint in a phase 3 clinical trial that evaluated the efficacy parameters of the drug for the treatment of Dravet syndrome. In the clinical trial, both the doses of Epidiolex (10 mg/kg/day and 20 mg/kg/day) demonstrated statistically significant improvements in the secondary endpoint parameters compared to a placebo therapy. GW Pharmaceuticals also completed patient recruitment for its phase 3 trial of Epidiolex for the evaluation of its safety and efficacy parameters for the treatment of individuals with Tuberous Sclerosis Complex. The company anticipates data from the clinical trial in the first half of 2019 and expects submission of a supplemental new drug application (or sNDA) to the FDA (Food and Drug Administration) in the second half of 2019. The label expansion of Epidiolex could significantly boost the sales growth of the drug. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Revenue trends In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year, reflecting ~1% YoY growth. In fiscal 2018, GW Pharmaceuticals’ net revenues grew ~15.75% YoY to reach $12.74 from $11.00. In the fourth quarter of 2018, GW Pharmaceuticals generated revenues of $10.5 million from product sales compared to $8.0 million in the same period the prior year, reflecting ~32% YoY growth. Wall Street analysts estimate that GW Pharmaceuticals will generate revenues of $8.8 million in the first quarter of fiscal 2019, which represents ~15.75% YoY growth. Analysts also estimate that GW Pharmaceuticals’ net revenues in fiscal 2019 will be around $122.66 million. GW Pharmaceuticals is strengthening its supply chain of Epidiolex. GW Pharmaceuticals’ regulatory filing for approval of Epidiolex in the European market is under review by the European Medicines Agency (or EMA). The company anticipates the EMA’s decision by the first quarter of fiscal 2019. The approval of the drug in the European market could significantly boost the revenue growth of GW Pharmaceuticals. ## Peers’ performance Cara Therapeutics (CARA) and Insys Therapeutics (INSY), GW Pharmaceuticals’ peers in the medical cannabis market, reported revenues of $5.0 million and $18.35 million, respectively, in the third quarter of fiscal 2018. Wall Street analysts estimate that Cara Therapeutics and Insys Therapeutics will report net revenues of $10.9 million and $83.74 million, respectively, in fiscal 2018. The revenue growth of GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics could boost the ETFMG Alternative Harvest ETF (MJ). GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics make up ~5.95%, ~1.52%, and ~1.64% of MJ’s total portfolio holding. In the next article, we’ll discuss GW Pharmaceuticals’ other earnings and operational expenditure trends. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
Cannabis Stock GW Pharmaceuticals Growing Steadily in January ## Stock performance On January 9, GW Pharmaceuticals (GWPH) stock rose ~1.81% to reach $119.54 from its prior day close of $117.41 on January 8. On January 7, the company’s stock price grew ~5.31% to reach $114.66 from its prior day close of $108.66 on January 4, 2019. On January 4, the company’s stock grew ~9.22% to reach $108.88 from its prior day close of $99.69 on January 3, 2019. GW Pharmaceuticals’ price of $119.54 on January 9 represents ~23% growth in the first six trading days of January 2, and this price is 33% below its 52-week high of $179.65 on September 27, 2018. On December 27, 2018, the company hit its 52-week low of $90.14. ## About GW Pharmaceuticals GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products. GW Pharmaceuticals’ Epidiolex oral solution has already received the FDA (Food and Drug Administration) approval for the treatment of individuals aged above two years with seizures related to Lennox-Gastaut syndrome or Dravet Syndrome. ## Analysts’ recommendations Of 13 analysts tracking GW Pharmaceuticals (GWPH) in January 2019, three of them recommended a “strong buy,” while eight analysts recommended a “buy” rating. One analyst recommended a “hold” rating, while one analyst recommended a “strong sell” for GW Pharmaceuticals in January. On January 10, GW Pharmaceuticals had a consensus 12-month target price of $173.17, which represents a ~44.86% return on investment over the next 12 months of this year. ## Peer ratings Of the five analysts tracking Supreme Cannabis Company (SPRWF) in January 2019, two of them recommended a “strong buy,” while three analysts recommended a “buy” rating. In January 2019, of the 11 analysts tracking Canopy Growth (CGC), two of them recommended a “strong buy,” seven recommended a “buy,” one recommended a “hold,” and one recommended a “sell” rating. Continue to Next Part Browse this series on Market Realist: * Part 2 - A Look into GW Pharmaceuticals’ Revenue Trends * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
CORAL GABLES, FL / ACCESSWIRE / January 10, 2019 / The way people receive health care, including how the medical field continues its integration of medical marijuana, is evolving. As public opinion surrounding cannabis becomes increasingly more favorable, marijuana stocks may begin to present an appealing opportunity for investors looking into the nascent sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), OrganiGram Holdings Inc (OGRMF), GW Pharmaceuticals Plc (GWPH), and Aphria Inc (APHA) represent 4 pot stocks that are heating up on Thursday.
One of the biggest health conferences of the year for investors, the J.P. Morgan Health-Care Conference, is taking place this week in San Francisco. BioMarin Pharmaceutical Inc. CEO Jean-Jacques Bienaimé said he would consider pursuing installment payment arrangements for the biotech’s experimental gene therapy for hemophilia. At the conference, Mr. Bienaimé told the Wall Street Journal that the one-time infusion, Valrox, is likely to cost in the millions because studies have shown it can eliminate bleeding episodes in patients, and current hemophilia treatments taken chronically can cost millions over several years.
Riding out the momentum of last year's monumental legislation, the sector has received much-need notoriety. Next Green Wave Holdings Inc (NXGWF) (NGW), Canopy Growth Corporation (CGC) (WEED.TO), Isodiol International Inc (ISOLF), and GW Pharmaceuticals plc (GWPH) are 4 pot stocks making headlines this month. Next Green Wave Holdings Inc (NXGWF) (NGW) is a vertically integrated seed-to-consumer premium medicinal and recreational cannabis company operating in California, the world's largest cannabis market.
Like other marijuana stocks, GW Pharmaceuticals (NASDAQ:GWPH) has struggled for the last three months. Despite its U.K.-base of operations, it has behaved similarly to the stocks of its Canadian peers. GWPH stock is down 20% in that time, while the ETFMG Alternative Harvest ETF (NYSEARCA:MJ) has lost close to 31%. However, a recent surge in the stock price coming into the new year has given hope to investors who saw the shares lose nearly half of their value in the final quarter of 2018. Moreover, due to the therapeutic potential of one of its drugs, it has received some degree of relief from the Schedule 1 designation that has hamstrung the cannabis business on a federal level. However, barring any major reforms to U.S. cannabis laws, a correct understanding of one key metric will probably continue to define the performance of GWPH stock. ### GWPH Avoiding Stigma Weighing on Other Marijuana Stocks Despite a name that implies a focus on pharma and biotech, the company happens to derive all of its treatments from cannabis. However, it benefits from one key difference. GW Pharma has effectively used cannabis to treat two rare but severe forms of childhood epilepsy. Due to this success, the company persuaded the DEA to redefine Epidolex as a Schedule 5 drug after it received FDA approval. This allows Epidolex to avoid the Schedule 1 status stigmatizing many other cannabidiol (CBD) products. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 A-Rated Safety Stocks for a Grossly Oversold Market GWPH has traded like a marijuana stock such as Canopy Growth (NYSE:CGC), Aurora (NYSE:ACB), or Tilray (NASDAQ:TLRY) in recent years. Since peaking in early October, it has fallen steadily, a fall that accelerated after cannabis in Canada became legal. Now, it has fallen by over 36% since that early October peak. All four stocks are among the top 10 holdings in the 35-stock portfolio comprising ETFMG Alternative Harvest. ### Common Metrics Hard to Apply Measuring whether an investor can consider GWPH stock a buy remains difficult, especially when measuring with more common metrics. The shares currently trade at around 290 times sales. However, that compares to 2018 revenues. Analysts forecast about 890% revenue growth in 2019 and an additional 260% in 2020. If those estimates prove correct, GWPH would trade at 8x 2020 revenues. Moreover, in one of the few cases of more marijuana suppressing an appetite, legalization killed the buzz surrounding Canadian marijuana stocks. However, if the U.S. experiences the same type of buildup toward legalization, investor interest could make a comeback. ### Look to the Moving Averages Nonetheless, this has not occurred yet. Many investors will take solace in the action seen in GW Pharmaceuticals stock in recent days and in the charts. Since an intra-day low of $90.14 per share on Dec. 27, the GWPH stock price has increased by 30%. Still, even with the move higher in recent days, GWPH trades below the 50-day and 200-day moving averages (MA). The moving averages seemed to have influenced the stock. In October, the 50-day MA switched from acting as a price floor to a price ceiling on GWPH. Moreover, until November, this 200-day MA appeared to serve as a secondary floor on the stock price. Once, the GWPH stock price broke through that floor, it did not stop falling until hitting that low in the low $90s per share range. * The 7 Best Stocks in the Entrepreneur Index Thanks to the recovery, GWPH stock closed Tuesday above $117 per share, near the 50-day MA of almost $123 per share. Here investors will find out whether the 50-day MA still serves as the ceiling. Even if it breaks through, investors will face the same question around the 200-day MA which now stands at about $138 per share. These lines could serve as an indicator as to whether GWPH has staged a comeback or finds itself in the midst of a dead-cat bounce. ### Bottom Line on GWPH Stock Considering a recent decline and partial recovery of GWPH stock, the moving averages will continue to influence the equity's performance. Before the October swoon and legalization in Canada, these MAs served as a floor on the GW Pharma stock price. However, both high valuations and a "sell the news" phenomenon hit GWPH after cannabis became legit north of the border. By November, the stock had fallen through the 200-day MA and then hit a trough at just above $90 per share. Now, with the stock marching higher at a rapid pace, it looks positioned to return quickly to these old inflection points. Whether these MAs serve as a floor or a ceiling on the price of GWPH stock will likely define the shares' performance in the months to come. Thanks to this post-Christmas recovery in GW Pharma stock, investors should know the answer to this question soon. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy Down 20% in December * 5 Chinese Stocks to Avoid Now (But Buy Later) * 3 Big Gainers That Easily Could Be the Best Stocks to Buy Compare Brokers The post Future of GW Pharmaceuticals Stock Hinges on Recent Floors and Ceilings appeared first on InvestorPlace.
CORAL GABLES, FL / ACCESSWIRE / January 7, 2019 / The beginning of the new year has already gotten off to a swift start for growth in the marijuana industry. Leafbuyer Technologies Inc (OTC:LBUY) announced today that it launched Phase One of its multiple phase blockchain initiative on December 20, 2018.
Now that one cannabis-based drug has won FDA approval, a wide range of drugmakers, from small biotech stocks to giant pharma firms, are exploring the substance to treat a host of maladies.
The New Year brought a shortened trading week. The deal flow didn’t stop, with recently-public TILT Holdings Inc (OTC: SVVTF ) announcing the acquisition of vaporization company Jupiter Research for $210 ...
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The beginning of the new year has already gotten off to a swift start for growth in the marijuana industry. With the new year in full swing, Leafbuyer Technologies Inc ( LBUY), GW Pharmaceuticals Plc (GWPH), New Age Beverages Corporation (NBEV), and Charlotte's Web Holdings Inc (CWBHF) (CWEB.CN) are 4 pot stocks worth looking into. Leafbuyer Technologies Inc (LBUY) is a company you may not have heard of, but could greatly benefit from looking into.
CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The marijuana industry has seen a huge boost this past year, which could spell out a true first-mover advantage as we head straight into the new year. With the new year just a few days old, CLS Holdings USA Inc (OTC:CLSH), New Age Beverages Corporation (TSX-V: NBEV), GW Pharmaceuticals Plc (NASDAQ: GWPH), and OrganiGram Holdings, Inc. (OTCQX: OGRMF) (TSX-V: OGI) are 4 pot stocks to keep your eyes on in the new year. CLS Holdings USA Inc (OTC:CLSH) is a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiaries.
The brokerage predicted that GW Pharmaceuticals’ cannabis-derived drug Epidiolex will eventually surpass $1 billion in annual sales.
NEW YORK, NY / ACCESSWIRE / January 3, 2019 / U.S. equities closed up on Wednesday after a volatile trading day, as investors remained concerned over the Fed’s tighter monetary policy and possible economic ...